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Legionnaires Disease in 
Immunocompromised Host
Venkat Rajasurya and Salim Surani
Abstract
Legionella bacteria are aerobic, pleomorphic, gram negative bacilli found in 
fresh water environments and are usually transmitted through inhalation aerosols 
from contaminated water or soil. Legionnaire’s disease is a severe form of pneu-
monia caused by legionella species and can be community acquired or hospital 
acquired. The reported incidence of Legionnaires’ disease is approximately 1.4–1.8 
cases per 100,000 persons and immunocompromised state is a very important risk 
factor. Some of the other important risk factors include old age, impaired cellular 
immunity, hematologic malignancies, solid organ transplantation, splenectomy, 
tumor necrosis factor-alpha inhibitors, chronic respiratory disease, diabetes and 
end stage renal disease. Legionella pneumophila serotype 1 is the most commonly 
reported cause of human Legionella infections. The pathogenesis of legionnaire’s 
disease involves invasion of alveolar macrophages and cell mediated immunity is 
the primary means of immune control. The prevalence of Legionnaires disease 
has risen possibly from increased awareness and reporting. The symptoms of the 
disease are nonspecific requiring a high index of suspicion in vulnerable hosts, as 
effective treatment could be life-saving. Sensitivity of urinary antigen testing is 
lower in immunocompromised patients because of higher likelihood of infections 
caused non L. pneumophila species. Extrapulmonary manifestations and higher 
mortality are particularly more common in immunocompromised patients than in 
immunocompetent hosts.
Keywords: transplant, legionnaires’ disease, immunocompromised patients, 
immunocompromised hosts
1. Introduction
Legionnaire’s disease is a severe form of atypical pneumonia caused by gram-
negative bacteria Legionella [1]. Although Legionnaire’s disease is commonly 
reported in immunocompetent patients, immunocompromised state, particularly 
impaired cellular immunity is an independent risk factor for legionella infection. 
Diabetes, hematologic malignancies, chronic corticosteroid use, solid organ trans-
plantation, TNF-alpha inhibitors are all risk factors for development of legionella 
infection [2]. Legionella micdadei, Legionella longbeachae, Legionella bozemanae, 
Legionella dumoffii and Legionella feeleii are some of the non-pneumophila species 
that predominantly cause infections in individuals with impaired immunity [3]. 
In immunosuppressed patients legionella can disseminate outside the lungs caus-
ing extrapulmonary manifestations like skin abscess, cellulitis, septic arthritis, 
myocarditis, endocarditis, peritonitis etc. [4]. Secondary to the increased incidence 
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Legionella testing should be routinely done in immunosuppressed patients present-
ing with symptoms suggestive of Community acquired pneumonia.
2. Anti-Legionella immunity
Legionella pneumophila is an intracellular pathogen that replicates within alveo-
lar macrophages. There are more than 60 species of legionella and out of which, 
serogroup 1 causes majority of legionella disease. Humans become infected after 
inhaling contaminated aerosols. L. pneumophila then enters and replicates within 
the lung alveolar macrophages. Bacteria are initially engulfed by phagocytes from a 
vacuole that blocks phagolysosome fusion by delivering bacterial proteins into host 
cell cytosol [5]. These proteins subsequently modulate endoplasmic reticulum and 
prevent lysosomal mediated killing of the bacteria. Another defense mediator of the 
body involves toll like receptors (TLR) on host cells, which senses various signaling 
proteins produced by L. pneumophila. This is in turn induces transcription factor, 
nuclear factor kappa B and produces inflammatory cytokines that sets up a potent 
immune response against L. pneumophila. A common genetic variation of the stop 
codon in the ligand binding domain of TLR increases the risk of acquiring legionella 
infection [6].
Tumor necrosis factor alpha is vital in protecting the body from L. pneumophila 
infection and the incidence of Legionnaires disease is reported to be higher in 
patients receiving TNF-alpha antagonists when compared to controls [7]. Defective 
monocytic-macrophagic system seen in hematological conditions can lead to the 
development of Legionnaire’s disease. T lymphocytes are essential for effective 
anti-legionella control but the exact role of B lymphocytes is unclear. Though some 
studies have highlighted the role of immunoglobulins during legionella infection 
an increased incidence of Legionnaire’s disease has not been found in patients with 
humoral immune deficiency [8].
3. Splenectomized patients
Legionella infection has not been frequently reported in splenectomized patients 
as these patients primarily have impairment in humoral immune response and 
B-lymphocyte function. A case report in 2004 reported two cases of Legionnaire’s 
disease in splenectomized patient. The first patient developed multiorgan failure 
and laboratory testing was positive for Legionella hackeliae and Legionella long-
beachae. The second patient was positive for Legionella micdadei [9]. Another 
patient with hairy cell leukemia and splenectomy died from multiorgan failure from 
L. longbeachae infection [10]. In 2012, Legionella pneumophila pneumonia was been 
reported in a patient with Myelodysplastic syndrome and splenectomy [11].
4. Primary immunodeficiencies
Primary immunodeficiency disorder is the result of defective immune system 
development and the absence of functional immune system leads to severe infec-
tions. There has been only one case of legionella pneumonia reported in a patient 
with primary immunodeficiency disorder. It was a 35-year-old male with hyper IgE 
disease who presented with hemoptysis and was later diagnosed to have cavitary 
pneumonia due to legionella which was isolated from the BAL cultures and the 
patient also had a positive urinary legionella antigen [12].
3Legionnaires Disease in Immunocompromised Host
DOI: http://dx.doi.org/10.5772/intechopen.89550
5. Organ transplant patients
Although there are many species of Legionella, L. pneumophila is the most com-
mon one to cause pneumonia in recipients of organ transplant. Among the non-pneu-
mophila species, L. micdadei, followed by L. longbeachae, L. bozemanii, L. parisiensis 
and L. cincinnatiensis commonly caused pneumonia in transplant recipients [3].
A Spanish group of physicians retrospectively reviewed 287 cases of Legionnaires’ 
disease in solid organ transplant patients. They reported that 3% of the transplant 
recipients had contracted Legionnaires’ disease. Incidence of legionnaire’s disease 
was variable but higher in kidney, lung and heart transplant patients [13].
Extrapulmonary manifestations of Legionella infection were described in four 
solid organ transplant patients. The extrapulmonary sites were aorta, pericardium, 
liver and soft tissue.
A group in Seattle, Washington reviewed 15 year longitudinal data in a hospital 
that cares for transplant patients and reported 32 cases of Legionnaires disease over 
a period of 15 years and 10 of them were in solid organ transplant patients [14].
6. Biologic agents
Biologic drugs are very commonly used for treatment of number of diseases and 
are associated with an increased risk of serious infections by lowering the immu-
nity. A study done in France in 2006 over a period of 1 year revealed a case series of 
10 patients treated with anti-TNF alpha therapy who were diagnosed with Legionella 
pneumophila infection [15]. Another French study that looked into risk factors for 
legionella infection from 2004 to 2007 concluded that anti TNF alpha therapy was 
associated with 13-fold increased risk of developing legionella infection. There was 
a 15-fold higher risk associated with infliximab, 38-fold higher risk associated with 
adalimumab and 3-fold increase with etanercept. Patients had different degrees 
of presentation. 28% presented with bilateral pneumonia, 24% had ARDS, 33% 
were hospitalized in ICU and 1 patient died [7]. A recent review from 2004 to 2011 
reported 105 cases of Legionnaire’s disease in patients treated with biologic treat-
ment [16].
7. Malignancies
Patients with hematological and solid tumors are at higher risk for developing 
legionnaire’s disease. A study found that Legionella caused 29% of pneumonia in 
patients with head and neck malignancies [17]. A retrospective study over 4 years 
conducted in a oncology center in 1986 found 36 cases of Legionnaire’s disease. 
42% had hematological malignancy and 22% had lung cancer. Neutropenic 
patients and patients on chronic steroids had higher risk of getting legionnaire’s 
disease [18].
Two retrospective studies were done at MD Anderson cancer hospital in Texas. 
First study reported 49 cases of Legionnaire’s disease in cancer patients over a 
period of 13 years from 1991 to 2003. The majority of patients had an underly-
ing hematologic malignancy. 37% were bone marrow transplant recipients. 
Lymphopenia, use of corticosteroids and chemotherapy were the most common risk 
factors in these patients [19]. Second retrospective study reviewed 33 consecutive 
cases of Legionnaire’s disease between 2002 and 2014. Out of this 27 had hemato-
logic malignancies, 23 had neutropenia, 6 had allogeneic hematopoietic stem cell 
transplant and all patients except 1 had lung infection [20].
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Clinical presentation of LD in immunocompromised patients:
Legionnaires disease in immunocompromised patients presents with fever, 
cough, chills, shortness of breath. GI symptoms can also occur. The incubation 
period for Legionnaires’ disease is usually around 2–10 days from the time of 
exposure to symptom onset. In immunocompromised patients in addition to 
consolidation legionnaire’s disease can present with cavitations, diffuse bilateral 
infiltrates and pleural effusions. In transplant patients nodular opacities that 
eventually cavitate have been reported [21]. Pleural effusions have been reported 
in 15–50% of cases.
Pneumonia with cavitation has been reported in L pneumophila serotypes 1, 3, 
4, 5, 6, and 8 as well as other Legionella species including L. micdadei, L. bozemanae, 
L. dumoffii, and L. longbeachae [22]. Legionella species can also cause lung abscesses 
and the most important risk factor for it is prolonged use of glucocorticoid therapy. 
Abscesses generally arise after 4 weeks of starting high dose glucocorticoid therapy. 
Complicated pleural effusions, empyema and lung abscesses caused by legionella 
are more commonly seen in patients with solid organ transplant [23].
Extrapulmonary manifestations are usually seen in immunocompromised hosts 
[4]. The incidence of Neurologic manifestations including meningoencephalitis, 
meningitis and transverse myelitis are similar to as in immunocompetent hosts. 
Cutaneous legionella has been reported in patients on chronic corticosteroids, solid 
organ transplants, stem cell transplants and hematological malignancies. They 
present with erythema, nodules, induration, ulcer or abscess. Most of them have 
concomitant lung infection [24].
Legionella can also affect the heart. L. pneumophila causing aortitis has been 
reported in heart transplant patients. Twelve cases of pericarditis were reported and 
most of them were in immunocompromised patients including transplant recipi-
ents, dialysis patients and cancer patients [25].
8. Conclusion
In conclusion while Legionella infection can occur in both immunocompetent 
and immunocompromised patients, certain risk factors in the immunocompro-
mised are associated with an increased incidence. T cell and cell mediated immu-
nity play a key role in body’s defense against the bacteria. TNF Alpha inhibitors 
are associated with an increased risk of Legionnaire’s disease. Extrapulmonary 
manifestations involving the skin, pericardium and aorta were seen more in 
immunocompromised, predominantly in patients on chronic corticosteroids, solid 
organ and stem cell transplant patients. The incidence of neurological manifesta-
tions remained the same. The signs and symptoms of Legionnaire’s disease are 
non-specific and patients with the above high risk features, especially on TNF alpha 
inhibitors should be screened for Legionella infection.
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